SERA logo

Sera Prognostics, Inc. Stock Price

NasdaqGM:SERA Community·US$142.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

SERA Share Price Performance

US$3.35
-4.79 (-58.85%)
US$3.35
-4.79 (-58.85%)
Price US$3.35

SERA Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward

Sera Prognostics, Inc. Key Details

US$108.0k

Revenue

US$126.0k

Cost of Revenue

-US$18.0k

Gross Profit

US$32.7m

Other Expenses

-US$32.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.86
-16.67%
-30,306.48%
0%
View Full Analysis

About SERA

Founded
2008
Employees
64
CEO
Evguenia Lindgardt
WebsiteView website
www.sera.com

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Recent SERA News & Updates

Will Sera Prognostics (NASDAQ:SERA) Spend Its Cash Wisely?

Oct 25
Will Sera Prognostics (NASDAQ:SERA) Spend Its Cash Wisely?

Recent updates

No updates